The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of  treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: amyloid precursor targeted therapies. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Amyloid precursor targeted therapies is a key innovation area in the pharmaceutical industry

Amyloid precursor targeted therapies aim to prevent or treat neurodegenerative disorders such as Alzheimer's disease by targeting accumulation of amyloid precursor proteins in the brain. These therapies use various peptides, immunogens, vaccines, antibodies, small molecule inhibitors, and nucleic acid sequences to enhance immune response and reduce amyloid deposition in the brain.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 80+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of amyloid precursor targeted therapies.

Key players in amyloid precursor targeted therapies – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to amyloid precursor targeted therapies

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
AC Immune 168 Unlock Company Profile
AFFiRiS 161 Unlock Company Profile
Pfizer 100 Unlock Company Profile
Johnson & Johnson 76 Unlock Company Profile
Perrigo 73 Unlock Company Profile
Axon Neuroscience 71 Unlock Company Profile
Prothena 70 Unlock Company Profile
Grifols 62 Unlock Company Profile
Eli Lilly 58 Unlock Company Profile
United Biomedical 42 Unlock Company Profile
Meiji 40 Unlock Company Profile
AbbVie 36 Unlock Company Profile
The Lundbeck Foundation 32 Unlock Company Profile
Apitope International 30 Unlock Company Profile
Kuros Biosciences 29 Unlock Company Profile
Novartis 27 Unlock Company Profile
ProMIS Neurosciences 26 Unlock Company Profile
MorphoSys 24 Unlock Company Profile
Saiba 24 Unlock Company Profile
F. Hoffmann-La Roche 24 Unlock Company Profile
Vaxxinity 21 Unlock Company Profile
IMV 18 Unlock Company Profile
Merck 15 Unlock Company Profile
Abbott Laboratories 14 Unlock Company Profile
Vitruvian Biomedical 12 Unlock Company Profile
PT Soho Global Health 12 Unlock Company Profile
Mercia Pharma 11 Unlock Company Profile
Kaketsuken 10 Unlock Company Profile
Centre National de la Recherche Scientifique 9 Unlock Company Profile
UK Research and Innovation 9 Unlock Company Profile
Forschungszentrum Julich 9 Unlock Company Profile
ImmunAid 8 Unlock Company Profile
Intra-Cellular Therapies 8 Unlock Company Profile
Cedars-Sinai Health System 8 Unlock Company Profile
Bristol-Myers Squibb 8 Unlock Company Profile
Tao Health Life Pharma 7 Unlock Company Profile
Alterity Therapeutics 7 Unlock Company Profile
Cava Healthcare 6 Unlock Company Profile
Amorfix Life Sciences 6 Unlock Company Profile
Immunotherapy Development 6 Unlock Company Profile
Manus Pharmaceuticals (Canada) 6 Unlock Company Profile
Massachusetts General Hospital 5 Unlock Company Profile
Intellect Neurosciences 5 Unlock Company Profile
Qantu Therapeutics 5 Unlock Company Profile
US Federal Government 5 Unlock Company Profile
Matsumoto Yushi-Seiyaku 5 Unlock Company Profile
Mclean Hospital 5 Unlock Company Profile
Codiak BioSciences 5 Unlock Company Profile
ADEL 5 Unlock Company Profile
Ramot 5 Unlock Company Profile

Source: GlobalData Patent Analytics

AC Immune is one of the leading patent filers in amyloid precursor targeted therapies. The company develops precision medicine for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and certain rare indications. The company’s lead assets include crenezumab and ACI‑24.060, which act by targeting amyloid precursor proteins.

In terms of application diversity, Eli Lilly leads the pack, while ADEL and Intra-Cellular Therapies stood in the second and third positions, respectively. By means of geographic reach, Axon Neuroscience held the top position, followed by Eli Lilly and Grifols.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.